Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Antiplatelet therapy

Cangrelor succeeds, at last, in PCI

Nature Reviews Cardiology volume 10, pages 302–304 (2013)Cite this article

Subjects

Cangrelor is an intravenous, reversibly binding, P2Y12-receptor inhibitor with a rapid onset of action that yields a high level of receptor inhibition within minutes. The CHAMPION PHOENIX study has demonstrated that these pharmacodynamic properties yield superior efficacy compared with oral clopidogrel loading at the time of percutaneous coronary intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Platelet activation and antiplatelet drugs.

References

  1. Bhatt, D. L. et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368, 1303–1313 (2013).

    Article  CAS  Google Scholar 

  2. Humphries, R. G., Robertson, M. J. & Leff, P. A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol. Sci. 16, 179–181 (1995).

    Article  CAS  Google Scholar 

  3. Storey, R. F. Biology and pharmacology of the platelet P2Y12 receptor. Curr. Pharm. Des. 12, 1255–1259 (2006).

    Article  CAS  Google Scholar 

  4. Bonello, L. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56, 919–933 (2010).

    Article  CAS  Google Scholar 

  5. Ahmad, S. & Storey, R. F. Development and clinical use of prasugrel and ticagrelor. Curr. Pharm. Des. 18, 5240–5260 (2012).

    Article  CAS  Google Scholar 

  6. Alexopoulos, D. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 5, 797–804 (2012).

    Article  CAS  Google Scholar 

  7. Steinhubl, S. R. et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res. 121, 527–534 (2008).

    Article  CAS  Google Scholar 

  8. Harrington, R. A. et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361, 2318–2329 (2009).

    Article  CAS  Google Scholar 

  9. Bhatt, D. L. et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361, 2330–2341 (2009).

    Article  CAS  Google Scholar 

  10. Angiolillo, D. J. et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307, 265–274 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Science, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK

    Robert F. Storey

Authors
  1. Robert F. Storey
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

R. F. Storey declares associations with the following companies: Accumetrics (institutional educational grant, institutional research support for consumables, consultancy fees, honoraria), AstraZeneca (institutional research grants, consultancy fees, honoraria), Bristol Myers Squibb (consultancy fees), Daiichi Sankyo (institutional educational grant, institutional research grants, consultancy fees, honoraria), Eisai (consultancy fees), Eli Lilly (institutional educational grant, institutional research grants, consultancy fees, honoraria), Iroko (honoraria), Medscape (honoraria), Merck (institutional research grants, consultancy fees, honoraria), Novartis (consultancy fees), Regeneron (consultancy fees), Roche (consultancy fees), and Sanofi Aventis (consultancy fees). Additionally, Prof. Storey was the first physician to administer cangrelor to a patient.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Storey, R. Cangrelor succeeds, at last, in PCI. Nat Rev Cardiol 10, 302–304 (2013). https://doi.org/10.1038/nrcardio.2013.61

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2013.61

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing